PMID- 35315784
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 1929-0748 (Print)
IS  - 1929-0748 (Electronic)
IS  - 1929-0748 (Linking)
VI  - 11
IP  - 3
DP  - 2022 Mar 22
TI  - Development of a Digital Health Intervention for Rheumatoid Arthritis Symptom 
      Management in a Biotechnology Industry Context: Protocol for the Application of a 
      Human-Centered Design Framework.
PG  - e16430
LID - 10.2196/16430 [doi]
LID - e16430
AB  - BACKGROUND: Involving chronically ill patients in the management of their health 
      is widely recognized as a vital component of high-quality health care. However, 
      to assume the role of informed participants, patients need both access to their 
      health information and assistance in interpreting such data. Smartphone 
      technology with SMS text messaging functionality offers a convenient and 
      minimally demanding mechanism for providing such dual capabilities to patients. 
      To date, a number of similar digital tools have been developed for use in various 
      chronic and progressive disease conditions, including rheumatoid arthritis. 
      OBJECTIVE: This paper aims to describe the development of a research protocol 
      that applies a human-centered design (HCD) approach to develop a mobile health 
      (mHealth) intervention to support symptom management and treatment adherence for 
      rheumatoid arthritis. METHODS: To guide the development of the mHealth 
      intervention for use within a commercial biotechnology context, we selected and 
      applied an HCD framework consisting of three phases: understanding, ideation, and 
      implementation. RESULTS: Leveraging the framework, we mapped the key objectives 
      and research questions to each phase and identified the HCD techniques and 
      methods most suitable for addressing them. In addition, we identified the need to 
      include a fourth phase, one that referred to postimplementation assessment, which 
      would enable evaluation of patient engagement and intervention impact on symptom 
      self-management. CONCLUSIONS: This paper presents a research protocol that 
      applied an HCD framework to guide the development of an mHealth intervention 
      within a commercial biotechnology context. This type of guidance is salient 
      because commercial entities are becoming one of the leading producers of this 
      type of intervention. However, the methodologies used and challenges faced from a 
      research and development perspective are not well-represented in the published 
      research literature to date. Our application of the HCD framework yielded 
      important findings. Each phase of the HCD framework provided important guidance 
      for increasing the likelihood that the final product would be understandable, 
      acceptable, feasible, and engaging to use. Consistent with other researchers in 
      the field of mHealth interventions, we identified the need to add a fourth phase 
      to the HCD framework, one that focused on a postimplementation assessment to 
      guide further improvements to support adoption in real-world settings. 
      INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): RR1-10.2196/16430.
CI  - (c)Lisa Nugent, Robin Anthony Kouyate, Shawna Jackson, Meredith Y Smith. Originally 
      published in JMIR Research Protocols (https://www.researchprotocols.org), 
      22.03.2022.
FAU - Nugent, Lisa
AU  - Nugent L
AUID- ORCID: 0000-0002-4219-9439
AD  - Amgen, Thousand Oaks, CA, United States.
FAU - Anthony Kouyate, Robin
AU  - Anthony Kouyate R
AUID- ORCID: 0000-0003-1554-6332
AD  - Amgen, Thousand Oaks, CA, United States.
FAU - Jackson, Shawna
AU  - Jackson S
AUID- ORCID: 0000-0002-3220-3369
AD  - Amgen, Thousand Oaks, CA, United States.
FAU - Smith, Meredith Y
AU  - Smith MY
AUID- ORCID: 0000-0003-4542-5099
AD  - Amgen, Thousand Oaks, CA, United States.
LA  - eng
PT  - Journal Article
DEP - 20220322
PL  - Canada
TA  - JMIR Res Protoc
JT  - JMIR research protocols
JID - 101599504
PMC - PMC8984827
OTO - NOTNLM
OT  - data visualization
OT  - digital journal
OT  - human-centered design
OT  - mobile phone
OT  - patient diaries
OT  - patient-reported outcomes
OT  - rheumatoid arthritis
COIS- Conflicts of Interest: At the time that this manuscript was developed, SJ, LN, 
      RAK, and MYS were full-time employees of Amgen Inc and held shares in the 
      company.
EDAT- 2022/03/23 06:00
MHDA- 2022/03/23 06:01
PMCR- 2022/03/22
CRDT- 2022/03/22 12:11
PHST- 2019/09/28 00:00 [received]
PHST- 2021/01/19 00:00 [accepted]
PHST- 2021/01/15 00:00 [revised]
PHST- 2022/03/22 12:11 [entrez]
PHST- 2022/03/23 06:00 [pubmed]
PHST- 2022/03/23 06:01 [medline]
PHST- 2022/03/22 00:00 [pmc-release]
AID - v11i3e16430 [pii]
AID - 10.2196/16430 [doi]
PST - epublish
SO  - JMIR Res Protoc. 2022 Mar 22;11(3):e16430. doi: 10.2196/16430.